Salarius Pharmaceuticals Inc (SLRX) — Cash Flow-to-Debt Ratio
Salarius Pharmaceuticals Inc (SLRX) has a Cash Flow-to-Debt Ratio of -0.89x as of September 2025, meaning its operating cash flow of $-1.65 Million could theoretically repay -1% of its total liabilities ($1.85 Million) in one year. Explore SLRX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Salarius Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Salarius Pharmaceuticals Inc across 10 annual periods. Also explore Salarius Pharmaceuticals Inc (SLRX) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Salarius Pharmaceuticals Inc (2015–2024)
Year-by-year debt coverage analysis for Salarius Pharmaceuticals Inc. For market capitalisation and broader financial context, see Salarius Pharmaceuticals Inc (SLRX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | — |